Neurocrine Biosciences, Inc. announced the launch of What THE C@H!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition. What THE C@H! was created for adults and adolescents living with CAH, parents of children with CAH and providers who treat the condition. Through a form on the website, people can submit their WHAT THE C@H! moment, a challenging experience of living with or managing the condition.

The website features educational information and offers patients and caregivers a space to share their CAH stories with others. CAH is a rare, genetic condition that results in an enzyme deficiency that alters the production of adrenal hormones which are essential for life. CAH is typically identified at or soon after birth and is associated with adrenal insufficiency that can lead to life-threatening adrenal crises and androgen excess.

People with CAH seek to achieve balance between cortisol deficiency and androgen excess through treatment with glucocorticoids, which have remained the standard for the past 70 years. However, side effects of treatment can be difficult to detect or distinguish from the symptoms of CAH itself, making it challenging to determine an appropriate treatment plan throughout various stages of life.